Seer board rejects two unsolicited acquisition offers citing undervaluation
Seer, Inc. announced that its Special Committee, composed of independent directors Meeta Gulyani and Nicolas Roelofs, Ph.D., has rejected two unsolicited acquisition proposals after a three‑month review. The offers, submitted on July 28, 2026 and July 29, 2026, valued the company at $2.55 and $2.45 per share in cash plus contingent value rights. The Committee concluded that a sale would not reflect Seer’s intrinsic value and the company will remain independent to pursue its proteomics strategy.
Why it matters
The rejection means no change in ownership or capital structure for shareholders, so existing equity holders retain full exposure to Seer’s future growth prospects. Analysts note that the decision keeps the stock’s valuation driven by organic performance rather than a merger premium.
Key facts
- 1The Special Committee, composed of Meeta Gulyani and Nicolas Roelofs, Ph.D., conducted a three‑month review of the proposals. stocktitan.net
- 2Bradley L. Radoff and Michael Torok submitted an unsolicited proposal on July 28, 2026 to acquire all outstanding Class A shares for $2.55 per share in cash plus a contingent value right. investing.com
- 3Omid Farokhzad, Seer’s Chair and CEO, submitted a separate proposal on July 29, 2026 for $2.45 per share in cash plus two contingent value rights. investing.com
- 4The Special Committee unanimously rejected both proposals, stating a sale would undervalue the company. stocktitan.net
- 5Seer will remain independent and continue focusing on its Proteograph proteomics product suite. tradingview.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.